{"id":"NCT01266902","sponsor":"Janssen R&D Ireland","briefTitle":"A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1","officialTitle":"An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2020-02","completion":"2020-02","firstPosted":"2010-12-24","resultsPosted":"2021-03-04","lastUpdate":"2021-03-04"},"enrollment":482,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"Rilpivirine","otherNames":[]}],"arms":[{"label":"Rilpivirine","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients who were randomized and treated with TMC278 in the Phase IIb or Phase III trials.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Up to 7 years","effectByArm":[{"arm":"Rilpivirine (RPV) (TMC278-C204 [C204])","deltaMin":32,"sd":null},{"arm":"RPV (TMC278-TiDP6-C209 [C209] and TMC278-TiDP6-C215 [C215])","deltaMin":70,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":98,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","China","Denmark","France","Germany","Netherlands","Puerto Rico","Romania","Russia","South Africa","Spain","Sweden","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":119},"commonTop":["Pregnancy","Syphilis","Alanine aminotransferase increased","Headache","Abdominal pain upper"]}}